Wolfgang Hammerschmidt

12.0k total citations · 1 hit paper
136 papers, 9.5k citations indexed

About

Wolfgang Hammerschmidt is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, Wolfgang Hammerschmidt has authored 136 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 65 papers in Epidemiology and 38 papers in Immunology. Recurrent topics in Wolfgang Hammerschmidt's work include Viral-associated cancers and disorders (98 papers), Cytomegalovirus and herpesvirus research (60 papers) and Lymphoma Diagnosis and Treatment (28 papers). Wolfgang Hammerschmidt is often cited by papers focused on Viral-associated cancers and disorders (98 papers), Cytomegalovirus and herpesvirus research (60 papers) and Lymphoma Diagnosis and Treatment (28 papers). Wolfgang Hammerschmidt collaborates with scholars based in Germany, United States and United Kingdom. Wolfgang Hammerschmidt's co-authors include Bill Sugden, Dagmar Pich, Henri‐Jacques Delecluse, Reinhard Zeidler, Andreas Moosmann, Aloys Schepers, Christoph Mancao, Georg W. Bornkamm, Markus Kalla and Alexander Buschle and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Wolfgang Hammerschmidt

132 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes

1989 473 citations Wolfgang Hammerschmidt, Bill Sugden profile →

Peers

Countries citing papers authored by Wolfgang Hammerschmidt

Since Specialization

Citations

This map shows the geographic impact of Wolfgang Hammerschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Hammerschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Hammerschmidt more than expected).

Fields of papers citing papers by Wolfgang Hammerschmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Hammerschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Hammerschmidt. The network helps show where Wolfgang Hammerschmidt may publish in the future.

Co-authorship network of co-authors of Wolfgang Hammerschmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Hammerschmidt. A scholar is included among the top collaborators of Wolfgang Hammerschmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Hammerschmidt. Wolfgang Hammerschmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model	Vaccines	Dagmar Pich, Wolfgang Hammerschmidt et al.	4
2	EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus–infected B cells	Proceedings of the National Academy of Sciences	Lucas E. Wange, Wolfgang Enard et al.	23
3	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test	PNAS Nexus	Dagmar Pich, Manuel Albanese et al.	5
4	Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection	PLoS Pathogens	Manuel Albanese, Alexander Buschle et al.	18
5	Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus	mBio	Mickaël Bouvet, Takanobu Tagawa et al.	40
6	Human ORC/MCM density is low in active genes and correlates with replication time but does not delimit initiation zones	eLife	Alexander Buschle, Xia Wu et al.	25
7	Epstein-Barr virus inactivates the transcriptome and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation	Nucleic Acids Research	Alexander Buschle, Paulina Mrozek-Górska et al.	20
8	CD27 is required for protective lytic EBV antigen–specific CD8+ T-cell expansion	Blood	Yun Deng, Bithi Chatterjee et al.	27
9	Structural basis of DNA methylation-dependent site selectivity of the Epstein–Barr virus lytic switch protein ZEBRA/Zta/BZLF1	Nucleic Acids Research	Johannes Günther, Alexander Buschle et al.	17
10	PLK1‐dependent phosphorylation restrains EBNA2 activity and lymphomagenesis in EBV‐infected mice	EMBO Reports	André Mourão, Piero Giansanti et al.	7
11	Epigenetic lifestyle of Epstein-Barr virus	Seminars in Immunopathology	Alexander Buschle, Wolfgang Hammerschmidt	74
12	Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection	Proceedings of the National Academy of Sciences	Paulina Mrozek-Górska, Alexander Buschle et al.	139
13	BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV	Life Science Alliance	Paulina Mrozek-Górska, Alexander Buschle et al.	35
14	Epstein–Barr virus microRNAs reduce immune surveillance by virus-specific CD8 ⁺ T cells	Proceedings of the National Academy of Sciences	Manuel Albanese, Takanobu Tagawa et al.	127
15	Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing	The Journal of Experimental Medicine	Takanobu Tagawa, Manuel Albanese et al.	105
16	RNAs in Epstein–Barr virions control early steps of infection	Proceedings of the National Academy of Sciences	Simon Jochum, Andreas Moosmann et al.	65
17	Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells	Blood	Andreas Moosmann, Iris Bigalke et al.	173
18	AP-1 homolog BZLF1 of Epstein–Barr virus has two essential functions dependent on the epigenetic state of the viral genome	Proceedings of the National Academy of Sciences	Markus Kalla, Dagmar Pich et al.	130
19	Epstein-Barr Virus Exploits BSAP/Pax5 To Achieve the B-Cell Specificity of Its Growth-Transforming Program	Journal of Virology	Rosemary J. Tierney, Claire Shannon‐Lowe et al.	34
20	High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus–free recombinant Epstein-Barr virus vectors	Experimental Hematology	Clemens‐Martin Wendtner, Christian Kurzeder et al.	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact